NASCAR rumors: Insider reveals Denny Hamlin's future with Joe Gibbs Racing
Denny Hamlin is near the front of the NASCAR starting grid for Nashville, but he might not race on Sunday as his first son is due to be born. With his family poised to grow even larger, there's even more incentive for the 44-year-old to sign a new Cup Series contract.
Jordan Bianchi of The Athletic writes that while Hamlin is in a contract year with Joe Gibbs Racing and is eligible for NASCAR free agency, there's a 'high probability' that he re-signs to drive the No. 11 car for the 2026 season.
'Working on it. Should be something done somewhat soon.'
Denny Hamlin on contract talks with Joe Gibbs Racing
Advertisement
Related: Denny Hamlin credits Kyle Busch for huge development in his career
Denny Hamlin stats 2025 (NASCAR.com): 390 points, 2 wins, 6 top 10s, 5 top 5s, 2 DNFs, 371 laps led, 12.357 average starting position, 15.231 average finishing position in 13 races
Hamlin, who will turn 45 years old ahead of the 2026 season, has spent his entire Cup Series career with Joe Gibbs Racing. While the No. 11 car lost its long-time partnership with FedEx after last season, the void was filled by a one-year deal with Progress Insurance.
A number of the top upcoming free agents in the NASCAR Cup Series have already signed new deals. Hendrick Motorsports signed William Byron to a contract extension and Richard Childress Racing confirmed Kyle Busch will be driving the No. 8 car next season.
Related: NASCAR free agents after this season, including Denny Hamlin
It leaves the biggest teams – Joe Gibbs Racing, Team Penske, Hendrick Motorsports and 23XI Racing – without any full-time openings for next season. As for some of the top NASCAR prospects, Connor Zilisch may spend another year in the Xfinity Series, while Corey Heim's timeline to become a full-time Cup Series driver seems further away.
Advertisement
With Hamlin all but confirmed to drive the No. 11 car for JGR next season, he'll have a great chance to achieve his long-standing goal of becoming one of the 10 winningest drivers in Cup Series history. Heading into the Cracker Barrel 400, Hamlin is four wins shy of tying Kevin Harvick for 10th all-time.
Related: NASCAR standings, see where Denny Hamlin sit in the points race
Related Headlines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
Edition Hotel's Latest Residences Offer Sweeping Views Of Nashville
The Residences at The Nashville Edition will offer luxury living in the heart of Music City. Located in Nashville's Gulch neighborhood, the boutique hotelier is offering 84 ultra-luxury private residences that will be situated across the top 15 floors of the city's new Edition hotel, with two half-floor penthouses occupying the very top. The condos range from one to four bedrooms, with pricing starting at around $1,650,000. Corcoran Sunshine Marketing Group, along with its local Nashville affiliate Corcoran Reverie, will exclusively lead the sales and marketing efforts; with units currently on sale to prospective buyers. The residences have been developed by Tidal Real Estate Partners and Left Lane Development, in collaboration with Marriott International and will join the brand's growing portfolio of unique, luxury hotels and residences which span across the United States, and beyond. 'With The Residences at The Nashville Edition, our goal is to build the finest residential building in this important American city,' said Mick Walsdorf, CEO of Tidal Real Estate Partners. 'Edition's warm and elegant interior aesthetics — as well as their true commitment to luxury — are in our view perfectly tuned for Nashville. We're proud to build on our past success delivering best-in-class residential offerings to important locales. This development is more than merely another hotel branded residence — it is a statement about where the city of Nashville is headed in its next chapter as a truly cosmopolitan destination known the world over.' Exteriors have been designed by by award-winning Nashville-based architecture firm ESa, with interiors by New York-based INC Architecture & Design. The glass tower will make a big impact on Nashville's skyline and will offer residents jaw-dropping views of the city and the Tennessee Hills from the condos' oversized windows. Owners will enjoy exclusive private services and amenities, as well as direct access to all that will be offered at The Nashville Edition Hotel. Exclusive amenities will include a dedicated lobby with concierge and valet services, a private state-of-the-art fitness center, a golf-simulator, private dining and multiple lounge areas. Seamless indoor-outdoor living will play a huge part in the residence community. Homes will feature private terraces, while a signature outdoor pool deck on the rooftop makes the perfect location for outdoor socializing throughout the southern summers. In addition, residences will have access to the hotel's pool, spa and restaurants.
Associated Press
an hour ago
- Associated Press
Quantum BioPharma Clarifies It Has Not Changed Its Name
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name. In addition, it has been brought to the attention of Quantum BioPharma that misinformation is being circulated on certain social media channels that Unbuzzd Wellness Inc., the company behind unbuzzd™, the scientifically-proven product that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is doing a reverse takeover transaction ('RTO') into Quantum BioPharma. Currently Unbuzzd Wellness Inc. is not doing a RTO transaction with Quantum BioPharma. Unbuzzd Wellness Inc. has hired leading audit firm MNP LLP ('MNP') effective May 20, 2025, to conduct Public Company Accounting Oversight Board ('PCAOB') audits of the Company's financial statements in preparation for a possible initial public offering ('IPO'). MNP, registered with the PCAOB, has the experience and proven track record to deliver audits of the highest standard. Hiring MNP follows the Company's announcement on February 5, 2025, regarding their retention of a New York investment bank to advise on a capital raise and explore an IPO, pending regulatory approval. Financial terms between Quantum BioPharma and Unbuzzd Wellness Inc. Currently Quantum BioPharma is the largest shareholder and debt holder of Unbuzzd Wellness Inc. Pursuant to the terms of their Agreement, Quantum will receive a 7% royalty on revenue from Unbuzzd Wellness Inc., until a total in the amount of $250,000,000 has been paid to Quantum, at which point the rate is reduced to 3%. In addition, Unbuzzd Wellness Inc. had issued Quantum 200,000,000 post-split common shares in the capital of the Unbuzzd Wellness Inc. ('Common Shares') as a licence fee and has issued Quantum an anti-dilution warrant, entitling Quantum to exercise the warrant any point in the next three years to increase their holding in the company to 25% for nominal consideration. On a go-public transaction, Quantum BioPharma will own at least 25% of Unbuzzd Wellness Inc. Unbuzzd Wellness Inc. and Quantum entered into a loan agreement, whereby Quantum loaned the Company $1,300,000 on secured basis with a term of 3 years, which will bear interest at a rate of 10% per annum, payable on each anniversary. Unbuzzd Wellness Inc.'s leadership team brings unparalleled experience and expertise to the table. The company is led by CEO John Duffy, a seasoned executive with a distinguished career at Coca-Cola Enterprises and The Coca-Cola Company. Duffy's vision is further complemented by the strategic guidance of beverage industry luminary and Unbuzzd Wellness Inc. Board Co-Chair Gerry David, the former CEO of Celsius Holdings, Inc., who played a pivotal role in establishing Celsius as a leading name in the beverage industry. Debt Settlement The Company also announces an authorized debt settlement for two vendors totaling USD$20,930 with Class B Shares that the board of directors of the Company (the 'Board') authorized. The Company intends to complete the Debt Settlements in or around the first week of June 2025. About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit About Unbuzzd Wellness Inc. The Company, a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class research and development team in pharmacology and medicine, with a commitment to innovation and quality. With a proprietary blend of vitamins, minerals and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly. unbuzzd appeals to a broad audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Scientifically-backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration, restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. The full press release of the clinical trial can be found here. unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at and unbuzzd is a registered trademark of the Company. Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE. For more information on Unbuzzd Wellness Inc. please visit Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as 'may', 'should', 'anticipate', 'expect', 'potential', 'believe', 'intend' or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those Quantum BioPharma Ltd. Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board Email: [email protected] Telephone: (833) 571-1811 Investor Relations Investor Relations: [email protected] General Inquiries: [email protected]
News24
an hour ago
- News24
Tongaat appoints Vision CEO to the helm amid ‘imminent' asset transfer
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
